about
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexitySafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.Haematological malignancies: at the forefront of immunotherapeutic innovation.Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN productionRepurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis.Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.Tumor suppressors in follicular lymphoma.Panobinostat: a review of trial results and future prospects in multiple myeloma.The safety of pomalidomide for the treatment of multiple myeloma.Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study.Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF/IRF3 pathway.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas.Thalidomide inhibits proliferation and epithelial-mesenchymal transition by modulating CD133 expression in pancreatic cancer cells.Antiangiogenic therapy for primitive neuroectodermal tumor with thalidomide: A case report and review of literature.Montelukast inhibits hypoxia inducible factor-1α translation in prostate cancer cells.Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer.IMiD compounds affect CD34 cell fate and maturation via CRBN-induced IKZF1 degradationOnline structure-based screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets
P2860
Q26771331-961E0C4A-CCE7-4982-A379-4AF4F34BD2ADQ33418964-C510957D-E892-4693-B3DB-F27D7E31143EQ33846806-E7074FE8-AD37-48D1-85EB-2BDB5EC3302EQ35880618-2CB8ACBB-5DA4-43BC-8E71-0863B6DF0F67Q37281544-6212BE04-7E77-4328-858E-630593534FBEQ37699414-50FBE945-9185-41D0-BD15-D8D430D87C0DQ37722551-A13B02C8-3418-4AFE-89CF-B25DF65B2C23Q38266066-26BF1E37-33D6-4C5E-BE0E-FD27F37126FBQ38269612-283906B5-D716-45EC-9ED4-E6E98A4F9FBCQ38749362-EDBCF0BC-2756-4AE2-947C-1782D83FF17FQ39248001-B16AD817-615F-473B-96C9-48C4D9D6D61FQ40006106-74850529-997D-4A6B-9B19-F274B7B11A31Q47898168-0C6752E1-95F6-4BBF-87C5-060137F70E71Q48017586-89D432B5-14EB-4879-8948-666E5EB527CEQ49212575-74C2D6E2-0850-4C15-82CB-044A72594F1CQ49452336-334E8048-3A74-4D44-9E76-5CA5F2299AE5Q52715671-7887AA93-5D07-4067-9DD0-ECCC1FF8BD1DQ52962540-663ECC75-7D47-4ABC-883B-4AFD146E1D6DQ58299695-84F3CF21-6276-4727-9FF1-72885B0D5FF0Q58767948-25CFD100-345D-44E9-A8C5-53FDB49C3D26
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Medicine. How thalidomide works against cancer
@ast
Medicine. How thalidomide works against cancer
@en
Medicine. How thalidomide works against cancer
@nl
type
label
Medicine. How thalidomide works against cancer
@ast
Medicine. How thalidomide works against cancer
@en
Medicine. How thalidomide works against cancer
@nl
prefLabel
Medicine. How thalidomide works against cancer
@ast
Medicine. How thalidomide works against cancer
@en
Medicine. How thalidomide works against cancer
@nl
P2860
P356
P1433
P1476
Medicine. How thalidomide works against cancer
@en
P2093
A Keith Stewart
P2860
P304
P356
10.1126/SCIENCE.1249543
P407
P577
2014-01-01T00:00:00Z